Bellicum Pharmaceuticals Gets $4.5M More

Houston-based Bellicum Pharmaceuticals, which is developing treatment for cancer and other chronic, infection diseases, has raised $4.5M more in funding, the company reported today. Bellicum said the new, Series A and convertible Note funding brings it total raised to $8.5M. Source of the new funding was not announced, however, the firm said it has now raised $1.45M from the Texas Emerging Technology Fund, $6.8M from angel investors, and the remainder from founders. Bellicum Pharmaceuticals is creating therapeutic vaccines, initially targeted at prostate cancer.